Sign up for our special edition newsletter to get a daily update on the coronavirus pandemic.

Medical giant Pfizer asked federal regulators on Tuesday to OK COVID vaccine booster shots for all adults — not just people in “high risk” categories.

Getting an extra dose of the Pfizer-BioNTech vaccine has already been an option for people older than 65, those with underlying health conditions and workers whose jobs mean they have a higher chance of exposure to the virus.

Emergency approval was given for those categories in September, but a Food and Drug Administration panel rejected a more widespread approval as questions lingered over whether healthy young people needed the additional dose at a time when much of the world is still unvaccinated.

Pfizer has submitted a study in its bid for more widely expanding access to booster shots that suggests the extra shot restores the vaccines protection against milder infection, according to the Associated Press.

The study, of 10,000 people, suggested a booster could push protection against symptomatic infection to 96 percent, with similar side effects to the first two doses, the AP said. The company said there were five people studied who got the booster jab and later had symptomatic COVID, while 109 people given a dummy shot had symptomatic infections.

People in high risk categories who got the two-shot Pfizer or Moderna vaccines can under the current rules get a booster six months later.

Those who got the Johnson & Johnson one-shot vaccine can get a booster two months later. J&J’s vaccine has shown lower effective rates than the other vaccines.

Federal regulators have already said it’s OK to mix and match the vaccine brands when getting the booster shot.

With Post wires